Asia
PKU HealthCare Gets Nod for Tofacitinib Citrate's Marketing
PKU HealthCare (SHE:000788) obtained approval from China's National Medical Products Administration for the marketing of Tofacitinib Citrate, according to a Shenzhen bourse filing on Friday.The drug is a potent Janus kinase (JAK) inhibitor, primarily used for patients suffering from chronic autoimmune conditions, including ankylosing spondylitis, rheumatoid arthritis and psoriatic arthritis.The healthcare company's share rose 1% during the afternoon trade.
SHE:000788
